Literature DB >> 23441652

Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.

N E Holmes1, J D Turnidge, W J Munckhof, J O Robinson, T M Korman, M V N O'Sullivan, T L Anderson, S A Roberts, S J C Warren, W Gao, P D R Johnson, B P Howden.   

Abstract

We reported an association between elevated vancomycin MIC and 30-day mortality in patients with Staphylococcus aureus bacteraemia (SAB), including patients with methicillin-susceptible S. aureus (MSSA) treated with flucloxacillin. A detailed analysis of comorbidities and disease severity scores in the same cohort of patients was performed to ascertain if unknown clinical parameters may have influenced these results. The association between elevated vancomycin MIC and 30-day mortality in SAB remained significant (p 0.001) on multivariable logistic regression analysis even when accounting for clinical factors. In addition, the association persisted when restricting analysis to patients with MSSA bacteraemia treated with flucloxacillin. This suggests that elevated vancomycin MIC is associated with but not causally linked to an organism factor that is responsible for increased mortality.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Bacteraemia; Staphylococcus aureus; comorbidity; mortality; vancomycin minimum inhibitory concentration

Mesh:

Substances:

Year:  2013        PMID: 23441652     DOI: 10.1111/1469-0691.12168

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  11 in total

1.  Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study.

Authors:  D M Martirosov; M R Bidell; M P Pai; M H Scheetz; S L Rosenkranz; T P Lodise
Journal:  Diagn Microbiol Infect Dis       Date:  2017-04-02       Impact factor: 2.803

2.  Reduced Vancomycin Susceptibility of Methicillin-Susceptible Staphylococcus aureus Has No Significant Impact on Mortality but Results in an Increase in Complicated Infection.

Authors:  Sean B Sullivan; Eloise D Austin; Stephania Stump; Barun Mathema; Susan Whittier; Franklin D Lowy; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

3.  Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.

Authors:  Whitney R Buckel; Shahira Ghobrial; Pranita D Tamma; Aaron M Milstone; Yuan Zhao; Alice J Hsu
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

4.  Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter?

Authors:  J Ruiz-Ramos; P Vidal-Cortés; A Díaz-Lamas; R Reig-Valero; F Roche-Campo; M Del Valle-Ortiz; X Nuvials-Casals; M Ortiz-Piquer; D Andaluz-Ojeda; L Tamayo-Lomas; M A Blasco-Navalpotro; M Rodriguez-Aguirregabiria; J Aguado; P Ramirez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-04-04       Impact factor: 3.267

5.  Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.

Authors:  Nicholas S Britt; Nimish Patel; Theresa I Shireman; Wissam I El Atrouni; Rebecca T Horvat; Molly E Steed
Journal:  J Antimicrob Chemother       Date:  2016-12-20       Impact factor: 5.790

6.  Vancomycin minimum inhibitory concentrations and lethality in Staphylococcus aureus bacteremia.

Authors:  Felipe Sulla; Daniel T Bussius; Felipe Acquesta; Alessandra Navarini; Suzethe M Sasagawa; Marcelo J Mimica
Journal:  Germs       Date:  2015-06-02

7.  Genetic and molecular predictors of high vancomycin MIC in Staphylococcus aureus bacteremia isolates.

Authors:  Natasha E Holmes; John D Turnidge; Wendy J Munckhof; J Owen Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Sanchia J C Warren; Geoffrey W Coombs; Hui-Leen Tan; Wei Gao; Paul D R Johnson; Benjamin P Howden
Journal:  J Clin Microbiol       Date:  2014-07-16       Impact factor: 5.948

8.  Impact of Molecular Epidemiology and Reduced Susceptibility to Glycopeptides and Daptomycin on Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  Hao-Yuan Lee; Chyi-Liang Chen; Shu-Ying Liu; Yu-Shan Yan; Chee-Jen Chang; Cheng-Hsun Chiu
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

Review 9.  Vancomycin revisited - 60 years later.

Authors:  Ethan Rubinstein; Yoav Keynan
Journal:  Front Public Health       Date:  2014-10-31

10.  Impact of prior healthcare-associated exposure on clinical and molecular characterization of methicillin-susceptible Staphylococcus aureus bacteremia: results from a retrospective cohort study.

Authors:  Pao-Yu Chen; Yu-Chung Chuang; Jann-Tay Wang; Shan-Chwen Chang
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.